Founded in 2007 and headquartered in RTP, North Carolina, BioMedomics is a privately-held, commercial-stage biotech and point-of-care diagnostic company.
Driven by a passion for innovation, BioMedomics has invested over $25 million in R&D and manufacturing, boasting a robust intellectual property portfolio with 15 core patents and 13 additional applications pending. The state-of-the-art research center spans 15,000 square feet, housing an ISO 13485-compliant manufacturing area equipped with cutting-edge instruments. But the greatest asset is the team: a group of highly talented individuals dedicated to R&D, manufacturing, quality systems, regulatory approvals, finance, sales, and marketing.
BioMedomics’ commitment to innovation is evident as follows:
-World’s leading manufacturer of hemoglobin S and hemoglobin F;
-World’s first rapid, POCT (point of care testing) Sickle SCAN ® for SCD (sickle cell disease) and trait;
-Global reach: Sickle SCAN ® and other products sold in over 40 countries with a worldwide network of distribution partners.

In November 2025, BioMedomics was acquired by OraSure Technologies, Inc., a global leader in point-of-care diagnostics and molecular sample management. This acquisition amplifies BioMedomics’ mission by combining our breakthrough sickle cell solutions with OraSure’s decades-long expertise in scaling life-saving diagnostics worldwide. With OraSure’s proven track record in infectious disease testing, global distribution channels, and regulatory excellence, BioMedomics is poised to accelerate innovation, expand access, and advance health equity worldwide. BioMedomics is currently a wholly-owned subsidiary of OraSure.